Our Platform

We will customize the experimental and technological approach for each discovery application.

Our antibody discovery platform uses industry-leading technologies and best-in-class humanized mice to discover high-quality antibodies for your target. For each phase of your project, we will carefully customize the experimental and technologic approach to ensure the success of your application.

Antigen Design and Immunization

The success of your antibody discovery project depends on the immune response to your antigen. Antigens must be properly designed for maximum immunogenicity. We will design and synthesize antigen for you, or we can start with antigen prepared by your team. Read more about the types of antigens and advanced immunization strategies here.

Model Choice

Our antibody discovery platform is centered around the in vivo discovery of antibodies produced in immunized mice.

For fully human antibody generation, we strongly recommend licensing the use of our RenMab/RenLite or RenMab/RenLite KO strains. Use of these humanized mice can accelerate the development of high-quality monospecific, bispecific, or multispecific antibodies for even difficult targets. 

For bioanalytical, anti-idiotype, surrogate or other applications that do not require fully human antibody discovery, we can immunize your preferred strain of wild-type mice.

Hit Generation

Our antibody discovery platform utilizes cutting-edge technologies to achieve real-time, single cell resolution of the screening process. Antigen-specific B cells are captured with efficiency and accuracy, without compromising throughput.  

From the animals that respond best to immunization, we will isolate lymphoid tissue and identify antibodies produced by individual B cells that have high affinity for your target. The positive cells are then captured and sequenced for further analysis.

Single B cell screening technologies

At Biocytogen, the industry-leading Beacon Optofluidic Technology is used in the majority of therapeutic antibody discovery applications to rapidly identify your antibody sequences of interest. For some challenging targets, FACS-based B-cell isolation can be used in combination with the Beacon platform to screen a variety of B cell subpopulations for hit generation, allowing for the maximum diversity of antibody clones.

Preserving your immune repertoire with phage display technology

If desired, display technology can be used to immortalize the in vivo immune response to your target antigen, allowing for future rounds of screening. This will maximize the yield from your discovery effort.

Depending on your application, display technology can also provide in vitro solutions for your discovery needs.

Lead Characterization

Lead Characterization involves further functional screening of antibody leads. In addition to secondary and tertiary screens, the biochemical and biophysical properties of antibody leads will be assessed to determine their developability. Our pharmacology experts will use both in vitro and in vivo platforms to provide comprehensive PK/PD (pharmacokinetic/pharmacodynamic) profiling and in vivo efficacy assessments. See a recent PK case study here.

Candidate Selection

At this phase in the discovery process, the top-performing antibody candidate(s) will ideally demonstrate maximum efficacy, safety, stability, and tolerability in preclinical models. A panel of experts across multiple disciplines will usually assess whether the candidate(s) will be suitable for clinical development.

Back to top